Charles Schwab
NYMX

Charles Schwab’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Charles Schwab’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-94,996
Closed -$211K – 3574
2021
Q1 		$211K Buy
94,996
+10,059
+12% +$26.5K ﹤0.01% 3311
2020
Q4 		$211K Hold
84,937
– – ﹤0.01% 3253
2020
Q3 		$209K Hold
84,937
– – ﹤0.01% 3164
2020
Q2 		$302K Buy
+84,937
New +$269K ﹤0.01% 3045
2019
Q2 		– Sell
-60,400
Closed -$119K – 3282
2019
Q1 		$119K Hold
60,400
– – ﹤0.01% 3082
2018
Q4 		$80K Hold
60,400
– – ﹤0.01% 3108
2018
Q3 		$149K Buy
60,400
+10,000
+20% +$29.5K ﹤0.01% 3101
2018
Q2 		$170K Hold
50,400
– – ﹤0.01% 3080
2018
Q1 		$214K Hold
50,400
– – ﹤0.01% 2972
2017
Q4 		$167K Hold
50,400
– – ﹤0.01% 3008
2017
Q3 		$193K Hold
50,400
– – ﹤0.01% 3019
2017
Q2 		$222K Buy
+50,400
New +$207K ﹤0.01% 2995

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TEE
Tibra Equities Europe London, United Kingdom $90.4M AUM 37.81% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Charles Schwab's NYMX Position: Q2 2021 in Review

Charles Schwab sold out of Nymox Pharmaceutical Corp (NYMX) in Q2 2021, closing a stake of 94,996 shares — an estimated $211K sold.

Charles Schwab first reported a position in NYMX in Q2 2017 and held it in 12 quarters. The position peaked at $302K in Q2 2020. 51 funds tracked by Wall St. Rank hold NYMX as of Q2 2021.

  • Charles Schwab reported no remaining Nymox Pharmaceutical Corp position as of Q2 2021 after selling out during the quarter.
  • Charles Schwab sold 94,996 Nymox Pharmaceutical Corp shares in Q2 2021, an estimated $211K.
  • Charles Schwab first reported a position in Nymox Pharmaceutical Corp in Q2 2017 and held it in 12 quarters.
  • Charles Schwab's Nymox Pharmaceutical Corp position peaked at $302K in Q2 2020.
  • 51 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q2 2021.

Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.